NeuroOne Medical Technologies Corporation
- Open
- 2.00
- Day high
- 2.24
- Day low
- 1.90
- Prev close
- 2.03
- Volume
- 0
- Mkt cap
- $19M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 5.2
- P/S
- 1.9
- Yield
- —
- Per share
- —
- ▼Insiders net selling -$32K over the last 3 months (0 open-market buys, 1 sale)
- 🏛Institutions reducing (13F)
NeuroOne Medical Technologies Corporation (NMTC) is a Healthcare company listed on NASDAQ. The stock is down 54% over the past year. Over the trailing 3 months, insiders filed 0 open-market buys and 1 sale (SEC Form 4). Drillr has 2 published research articles covering NMTC.
NeuroOne Medical Technologies Corporation (NMTC) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
NMTC earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Aug 13, 2026 | $-0.21 | $-0.28 | -33.3% | $2M | -8.9% |
| May 12, 2026 | $-0.23 | $-0.25 | -10.3% | $2M | -7.2% |
| Feb 17, 2026 | $-0.03 | $-0.03 | +0.0% | $3M | +17.2% |
| Dec 17, 2025 | $-0.04 | $-0.04 | -0.8% | $3M | +11.0% |
| Aug 14, 2025 | $-0.05 | $-0.03 | +40.0% | $2M | -19.3% |
| Feb 12, 2025 | $-0.10 | $0.06 | +160.0% | $3M | +55.9% |
| Dec 17, 2024 | $-0.09 | $-0.11 | -22.2% | $272284 | -84.9% |
| Aug 14, 2024 | $-0.09 | $-0.10 | -11.1% | $825776 | -51.4% |
| May 14, 2024 | $-0.10 | $-0.11 | -10.0% | $1M | -19.0% |
| Feb 13, 2024 | $-0.14 | $-0.14 | +0.0% | $977649 | +15.0% |
| Dec 14, 2023 | $-0.17 | $-0.13 | +23.5% | $741780 | -7.3% |
| Aug 14, 2023 | $-0.20 | $-0.20 | +0.0% | $629906 | -21.3% |
NMTC insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Jul 2, 2026 | Christianson Markofficer: Market Development Director | Sell | 10,000 | $3.18 |
| Apr 7, 2026 | Mills Jason Richarddirector | Grant | 41,929 | — |
| Apr 7, 2026 | Mills Jason Richarddirector | Grant | 26,036 | $0.80 |
| Apr 7, 2026 | MATHIESEN JEFFREY Sdirector | Grant | 41,929 | — |
| Apr 7, 2026 | MATHIESEN JEFFREY Sdirector | Grant | 26,036 | $0.80 |
| Apr 7, 2026 | BUCKMAN PAULdirector | Grant | 41,929 | — |
| Apr 7, 2026 | BUCKMAN PAULdirector | Grant | 26,036 | $0.80 |
| Apr 7, 2026 | Andrle Edwarddirector | Grant | 26,036 | $0.80 |
| Apr 7, 2026 | Andrle Edwarddirector | Grant | 41,929 | — |
| Mar 16, 2026 | Christianson Markofficer: Business Development Director | Sell | 100 | $0.80 |
| Mar 16, 2026 | Christianson Markofficer: Business Development Director | Sell | 817 | $0.80 |
| Mar 12, 2026 | Christianson Markofficer: Business Development Director | Sell | 11,611 | $0.80 |
| Mar 12, 2026 | Christianson Markofficer: Business Development Director | Sell | 2,109 | $0.80 |
| Feb 20, 2026 | Mertens Steveofficer: Chief Technology Officer | Tax | 7,376 | $0.68 |
| Feb 20, 2026 | Rosa David Adirector, officer: CEO and President | Tax | 71,325 | $0.68 |
Source: NMTC SEC Form 4 filings, latest Jul 2, 2026. For informational purposes only — not investment advice.
See the full NMTC insider & 13F page →NMTC research & analysis
FDA Drops Sham Control for Rare-Disease Gene Therapy (CLPT, QURE)
The FDA told uniQure a sham-surgery control is no longer required, moving the cost of rare-disease gene therapy onto delivery hardware and endpoint instruments.
BCDABIIBCLPTuniQure (QURE), ClearPoint (CLPT): FDA Drops Sham-Surgery Control
uniQure, ClearPoint and BioCardia disclosed the FDA no longer requires a sham-surgery control in rare CNS gene therapy, moving the gate to delivery hardware.
BCDACLPTCYRX
NeuroOne Medical Technologies Corporation company profile
Overview
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) is a medical technology company founded in 2014 and headquartered in Eden Prairie, Minnesota. The company went public in March 2018 and specializes in developing innovative thin-film electrode technologies for treating neurological disorders. NeuroOne has evolved from a research-stage company to a commercialized medical device manufacturer, with its flagship OneRF ablation system receiving FDA clearance in 2024. The company has established strategic partnerships with major medical device companies, most notably Zimmer Biomet, to distribute its products globally.
Business
NeuroOne operates in the neurological medical device industry, focusing on minimally invasive treatments for brain and nervous system disorders. The company's core technology platform centers around proprietary thin-film electrodes that can both record electrical activity from the brain and deliver therapeutic treatments. The company's primary product is the OneRF Ablation System, which represents a breakthrough in epilepsy treatment. Traditional epilepsy surgery requires patients to undergo two separate hospitalizations - first for diagnostic brain mapping using implanted electrodes, then a second surgery for treatment. NeuroOne's system uniquely combines both functions in a single device, allowing surgeons to record brain activity to locate seizure sources and then immediately ablate (destroy) the problematic tissue using radiofrequency energy, all during one hospitalization. NeuroOne also manufactures the Evo sEEG electrode for stereoelectroencephalography, which is used purely for diagnostic brain mapping in epilepsy patients. This product is distributed through their partnership with Zimmer Biomet and competes in the traditional diagnostic electrode market. The company is expanding into additional neurological applications including trigeminal neuralgia treatment (facial pain), spinal cord stimulation for chronic pain management, and exploring drug delivery systems that could deliver medications directly to specific brain regions through their electrode platform. Based on recent financial disclosures, the OneRF and Evo product lines represent virtually 100% of current product revenue, with the OneRF system expected to drive the majority of future growth.
Revenue model
NeuroOne generates revenue through two primary channels: direct product sales and licensing agreements. The company sells its medical devices directly to hospitals and surgical centers, with individual OneRF procedures generating revenue from both the electrode hardware and associated consumables. Product gross margins have improved dramatically from 31% in fiscal 2024 to projected 47-51% in fiscal 2025, reflecting manufacturing scale and operational efficiency gains. The company's major revenue driver is its strategic partnership with Zimmer Biomet, which provides both upfront licensing payments and ongoing product sales. In fiscal 2025, NeuroOne received a $3 million upfront license payment and expects the majority of its projected $8-10 million annual revenue to flow through this partnership channel. Zimmer Biomet handles distribution, sales, and customer relationships, while NeuroOne focuses on manufacturing and product development. Several factors influence NeuroOne's profitability margins. Positive margin drivers include the company's proprietary technology creating pricing power, manufacturing scale efficiencies as volumes increase, and the high-value nature of neurological procedures that can support premium pricing. The single-hospitalization benefit of the OneRF system provides significant cost savings to healthcare systems, supporting favorable reimbursement dynamics. Margin pressures come from the highly regulated medical device environment requiring substantial R&D investment, the need for extensive clinical validation and FDA approvals for new applications, and dependence on a limited number of specialized manufacturing partners. Competition from established medical device companies with larger sales forces and broader product portfolios also constrains pricing flexibility. Additionally, the company's small scale means fixed costs like regulatory compliance and quality systems represent a higher percentage of revenue compared to larger competitors.
Competitive moat
NeuroOne possesses a moderate but potentially strengthening competitive moat based primarily on its proprietary thin-film electrode technology and regulatory barriers. The company's core advantage lies in being the first and only FDA-cleared system that can perform both brain recording and ablation functions with the same electrode, creating a unique clinical value proposition that reduces patient risk and hospital costs through single-hospitalization treatment. The company's intellectual property portfolio around thin-film electrode manufacturing and the combination recording/ablation functionality provides some protection, though the durability of this advantage depends on continued innovation and patent defense. The regulatory moat is significant, as competitors would need to conduct extensive clinical trials and navigate complex FDA approval processes to offer similar combination devices. However, the moat faces several vulnerabilities. Large medical device companies like Medtronic, Boston Scientific, and Abbott have substantially greater resources for R&D, clinical trials, and market access, and could potentially develop competing technologies or acquire smaller innovators. The neurological device market is highly specialized, and established relationships between these larger companies and neurosurgeons create switching costs that favor incumbents. NeuroOne's partnership strategy with Zimmer Biomet both strengthens and potentially weakens its position - while providing essential distribution capabilities and market credibility, it also creates dependence on a partner's priorities and sales execution. The company's small scale limits its ability to invest in clinical studies that could expand its evidence base and market applications. Overall, NeuroOne has carved out a defensible niche, but maintaining its competitive position will require continued innovation and successful execution of its product expansion strategy.
Risks & safety
NeuroOne presents a moderate to high financial risk profile typical of a small-cap medical device company in growth phase, with improving but still concerning cash flow dynamics. **Cash and Debt Position:** - Cash and short-term investments: $1.32 million as of Q2 2025 - No outstanding debt, providing clean balance sheet - Recent $8.2 million capital raise provides funding through fiscal 2026 - Quarterly cash burn averaging $2-3 million based on recent operating cash flows **Profitability Metrics:** - EBITDA negative $2.2 million in Q2 2025, though improving from prior periods - Net margins remain deeply negative despite revenue growth - Free cash flow negative $59,315 in Q2 2025, significantly improved from prior quarters **Valuation Concerns:** - Price-to-book ratio of 23.5x indicates substantial premium to tangible assets - Current ratio of 2.13x provides adequate short-term liquidity cushion - Market cap of approximately $29 million against projected $8-10 million annual revenue suggests high growth expectations are priced in **Other Considerations:** - Revenue concentration risk with Zimmer Biomet partnership representing majority of sales - Regulatory dependency for new product approvals could impact growth trajectory - Small public float and limited institutional coverage create liquidity constraints
Recent development
Over the past two years, NeuroOne has transformed from a pre-revenue development company to a commercialized medical device manufacturer through several key strategic initiatives. The most significant milestone was receiving FDA 510(k) clearance for the OneRF Ablation System in 2024, making it the first and only approved device capable of both recording brain activity and performing ablation therapy with the same electrode. The company has strategically expanded its partnership with Zimmer Biomet beyond the original Evo sEEG electrode distribution agreement to include the OneRF system, receiving a $3 million upfront licensing payment and positioning Zimmer Biomet as the primary distribution channel. This partnership approach allows NeuroOne to leverage Zimmer Biomet's established relationships with neurosurgeons and hospital systems while focusing internal resources on product development and manufacturing. NeuroOne is actively diversifying its product portfolio beyond epilepsy treatment, with a 510(k) submission planned for the first half of 2025 for trigeminal neuralgia (facial pain) treatment using the same RF ablation technology. The company is also developing applications for spinal cord stimulation and exploring drug delivery systems that could deliver medications directly to specific brain regions through their electrode platform. Recent organizational developments include adding Dr. Parag Patil as Chief Medical Advisor to support clinical development and establish patient outcome registries for potential publication, strengthening the company's clinical credibility. The company has also initiated ISO 13485 certification to enable international market expansion beyond the current U.S. focus. These strategic moves position NeuroOne to capitalize on its core technology platform across multiple neurological applications while building the clinical evidence base needed for broader market adoption.
NMTC company profile · for informational purposes only — not investment advice.
Track NMTC with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free